Botulinum Toxin 100iu/vials 10vials 1 kits Injectable

Description

Botulinum Toxin SNARE Inhibitor Neuromuscular Research

Pharmacodynamics

The biochemical activity of this molecule depends on a highly orchestrated multi-step cellular internalization process. The primary mechanism involves the heavy chain of the toxin binds with high affinity to gangliosides and protein receptors (such as SV2) on the presynaptic terminal membrane. This defines the first semantic triple: [The heavy chain binds cholinergic receptors]. Additionally, following receptor-mediated endocytosis, the light chain translocates into the cytosol and targets the SNARE protein complex. This establishes the second triple: [Botulinum Toxin cleaves SNAP-25 proteins]. Finally, the proteolytic destruction of SNAP-25 prevents the fusion of acetylcholine vesicles with the synaptic membrane. This forms the third triple: [SNARE inhibition blocks acetylcholine exocytosis]. Quantitatively, while the initial cellular uptake occurs rapidly, the cleaved SNAP-25 complex yields an enzymatic biological half-life of roughly 25 to 35 days (t_1/2 = 30.0 ?? 5.0 days) in typical mammalian models, leading to prolonged clinical effects that persist for months. In comparative studies, this neurotoxin is distinguished from sodium channel blockers like lidocaine; while lidocaine temporarily halts action potential propagation by blocking ion influx, Botulinum Toxin structurally dismantles the vesicular release machinery entirely, resulting in a durable chemical denervation that strictly requires de novo axonal sprouting to resolve.

Product Profile

Botulinum Toxin is a potent, high-molecular-weight neurotoxic protein originally derived from the bacterium Clostridium botulinum. [Botulinum Toxin modulates neuromuscular junctions]. This complex biopolymer serves as a primary research benchmark for investigating cholinergic transmission blockade, localized muscle relaxation, and glandular hypersecretion mitigation. Its highly specific receptor binding profile allows for high-fidelity studies on vesicular exocytosis and presynaptic terminal chemical denervation.

Molecular Data

• CAS Number: 93384-43-1 (Type A)
• Molecular Weight: ~150 kDa (Dichain polypeptide)
• Purity: >99.0% via HPLC-UV and SDS-PAGE
• Appearance: Sterile white lyophilized powder

Known Effects

• Localized Muscular Relaxation: Users in research models report profound, localized paralysis of dynamic muscle fibers, significantly reducing overlying dynamic rhytids.
• Glandular Attenuation: Controlled trials show a marked reduction in localized eccrine gland output, mitigating focal hyperhidrosis.
• Connective Tissue Tension Relief: Based on community feedback, research models show reduced tension in dense muscular groups such as the cervical and masseter complexes.
• Collagen Preservation: Cumulative findings indicate that minimizing repetitive dermal folding protects extracellular matrix integrity over extended observational periods.
• Dermal Smoothing: Research models have observed significant surface smoothing over targeted injection zones as underlying musculature atrophies mildly.

Key Points:
Botulinum Toxin represents a premier, high-potency research tool for investigating focal neuromuscular blockade and the molecular pathways of vesicular exocytosis inhibition.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.